drugset / Trial / NCT00101972
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating patients with metastatic or recurrent adenocarcinoma.
Timeline
- Start
- 2004-12
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAV12 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 0.75 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | RAV12 | Monoclonal antibody | 6 mg/kg | Intravenous |